1593542-96-1

Basic information

• Product Name: (3R,4R)-1-(4-fluorophenyl)-3-((R)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one
• Synonyms: (3R,4R)-1-(4-fluorophenyl)-3-((R)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one;(3R,4R,3'R)-Ezetimibe;(3'R,3R,4R)-Ezetimibe
• CAS NO: 1593542-96-1
• Molecular Formula: C₂₄H₂₁F₂NO₃
• Molecular Weight: 409.4252464
• Mol File: 1593542-96-1.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: (3R,4R)-1-(4-fluorophenyl)-3-((R)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,4R)-1-(4-fluorophenyl)-3-((R)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one(1593542-96-1)
• EPA Substance Registry System: (3R,4R)-1-(4-fluorophenyl)-3-((R)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one(1593542-96-1)

Safety Data

• Hazardous Substances Data: 1593542-96-1(Hazardous Substances Data)

Usage

Uses

(3’R,3R,4R)-Ezetimibe is a structural analog of Ezetimibe (E975000); an antihyperlipoproteinemic and a cholesterol absorption inhibitor.

Upstream product

• 1478663-95-4 (S)-3-((R)-2-((R)-(4-((tert-butyldimethylsilyl)oxy)phenyl)((4-fluorophenyl)amino)methyl)-4-(2-(4-fluorophenyl)-5,5-dimethyl-1,3-dioxan-2-yl)butanoyl)-4-phenyloxazolidin-2-one 

Relevant articles and documents

First synthesis and characterization of key stereoisomers related to Ezetimibe

During the laboratory optimization and the late phase manufacturing studies of the cholesterol absorption inhibitor Ezetimibe 1, the formation of several stereoisomers was observed. To study the complete stereoisomer profile of Ezetimibe 1, we have synthesized and completely characterized several key stereoisomers of Ezetimibe 1 for the first time. This study will provide an access to the reference standard of these stereoisomers and may have some implications in the development of new medicines.